Abstract
Chemotherapy-induced cardiotoxicity and heart failure have become significant concerns in cancer treatment. Advancements in cancer therapies have increased survival rates, with consequent increase in the prevalence of chemotherapy-induced cardiotoxicity and subsequent heart failure. Guideline-directed medical therapy (GDMT) has emerged as a crucial approach for managing these conditions. GDMT encompasses evidence-based medications and interventions backed by clinical guidelines that aim to optimize the treatment and outcomes of heart failure. This review critically summarizes the existing evidence on the roles of GDMT in the management and prevention of chemotherapy-induced cardiotoxicity and heart failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
